Abstract library

497 results for "Lowe".
#712 A Retrospective Analysis of Safety and Efficacy of Everolimus in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients That Showed Progression after PRRT
Introduction: GEP-NET patients have been treated successfully with SSAs. Upon progression, peptide receptor radiotherapy (PRRT) with 177Lu-octreotate is successful. PRRT is not unlimited. Some patients became refractory after therapy. There is a high medical need. Everolimus (mTOR inhibitor) is a promising therapy for progressive G1/G2 GEP-NETs, with well-established safety. Everolimus has shown efficacy in patients with (non-)PNET (RADIANT-2/-3). However, toxicity data of Everolimus after PRRT is lacking.
Conference: 10th Annual ENETS Conference (2013)
Category: Medical treatment - Targeted therapies
Presenting Author: drs. Kimberly Kamp
#1743 FOLFIRI Regimen with or without Bevacizumab As Second-Line Therapy Showed Activity in Patients with Metastatic Gastroenteropancreatic Neuroendocrine Carcinoma
Introduction: Metastatic disease of GEP-NEC is tough condition in clinical practice. And the role of the second-line therapy remains unknown
Conference: 14th Annual ENETS conference (2017)
Category: Medical treatment – Chemotherapy, medical treatment - others
Presenting Author: ASS PROF Zhiyu Chen
Authors: Chen Z, Zhao X, Wang C, Zhang W, ...
Keywords: NEC, FOLFIRI, bevacizumab
#923 A Case Report of a Pancreatic Neuroendocrine Tumor (pNET) With High Levels of 5-HIAA in Urine
Introduction: A 79-year-old man presented with weakness and weight loss. Clinical examination revealed a palpable liver and CT scan a mass in the head of pancreas and multiple liver lesions.
Conference: 11th Annual ENETS Conference (2014)
Category: Clinical cases/reports
Presenting Author: Dr Nikolaos Tsoukalas
Keywords: 5-HIAA, pancreas, pNET
#1055 Neuroendocrine Pancreatic Tumor Associated with a Cerebral Neurofibroma. A Case Report.
Introduction: Neuroendocrine pancreatic tumors (pNET) are rare in young patients. They usually occur in the setting of genetic syndromes.
Conference: 12th Annual ENETS Conference (2015)
Category: Clinical cases/reports
Presenting Author: Doctor Valbona Lico
#1154 Selective Internal Radiation Therapy (SIRT) Radioembolisation with 90 Yttrium in Patients with Unresectable Liver Neuroendocrine Metastases in a Specialized Center. An Initial Report
Introduction: Most patients with neuroendocrine tumors present liver metastases at some point of the clinical course. Liver directed treatment, such as 90 Yttrium is a method of treatment used in patients with non-resectable liver lesions, which is effective in the control of symptoms and tumor growth.
Conference: 12th Annual ENETS Conference (2015)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: Juan Manuel O'Connor
#1464 A Case of Multiple Pancreatic Insulinoma Laparoscopically Resected through Precise Spatial Diagnosis by SACI Test
Introduction: Case: A 58-year-old man representing cold sweat, palpitation and nausea was admitted to our hospital and was pointed out parathyroid, pancreatic and superior mediastinal masses with CT.
Conference: 13th Annual ENETS conference (2016)
Category: Clinical cases/reports
Presenting Author: Kenzo Nakano
Authors: Nakano K, Masui T, Sato A, Ito T, ...
#2002 Pulmonary Function Test Physiology and Progression in Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia
Introduction: Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH) is a rare condition characterised by a generalised proliferation of pulmonary neuroendocrine cells within the respiratory epithelium. Little is known of its affects on pulmonary function both at the time of diagnosis and prospectively.
Conference: 15th Annual ENETS conference (2018)
Category: Non digestive NETs (bronchial, thymic, others) - diagnosis and therapy
Presenting Author: Joseph Barlow
Authors: Barlow J, Ryan D, Mansoor W, Howell M, ...
#2190 A Prospective Nordic Study on the Use of Chromogranin A for the Prediction of Progression in Patients with Pancreatic and Small Intestinal Neuroendocrine Tumors
Introduction: Retrospective studies showed that changes in plasma chromogranin A (CgA) might predict change in tumor burden in gastroenteropancreatic neuroendocrine tumor (GEP-NET) patients.
Conference: 15th Annual ENETS conference (2018)
Category: Biomarkers
Presenting Author: Gitte Dam
Keywords: gep-net, ct, cga, correlation
#66 Adrenocortical cancer: a therapeutic approach with everolimus (RAD001)
Introduction: Adrenocortical cancer (ACC) is a rare disease with very poor outcome. ACC responds poorly to standard chemotherapy. Mitotane, used as adjuvant therapy to surgery, prolongs recurrence-free survival, but the response is limited to 23% of patients and resistance occurs in the majority of patients (1). There is no curative therapy for ACC. Pre-clinical studies have shown involvement of both IGF-2/IGF-1R and Akt/mTOR pathways in ACC, and IGF-1R and mTOR inhibitors inhibited cell proliferation of human adrenocortical carcinoma cell lines in vitro (2,3,4).
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Maria Gueorguiev
#69 Frequent biological association of Merkel cell polyomavirus with Merkel cell carcinomas
Introduction: Merkel cell polyomavirus (MCPyV) DNA has been detected by PCR in 75–100% of Merkel cell carcinomas (MCC), an aggressive neuroendocrine skin cancer. MCPyV is a 5.4 kb DNA virus that expresses tumor (T) antigen in tumor tissues.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: Dr Ernst-Jan M Speel